Richard Fang was named Chief Executive Officer of Picard Medical, Inc. As of November 6, 2026, Picard Medical, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 2, 2026 to November 3, 2026, naming 5 appointments (Form 8-K, November 3, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Picard Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Richard Fang · Role: Chief Executive Officer · 8-K, 2026-11-03
- · In / out: In · Person: Joe Xiao · Role: Director · 8-K/A, 2026-07-07
- · In / out: In · Person: Joe Xiao · 8-K, 2026-06-29
- · In / out: In · Person: Richard Fang · Role: Chief Executive Officer · 8-K, 2026-06-24
- · In / out: In · Person: Georgina Smith · Role: Chief Accounting Officer · Effective: 2026-06-01 · 8-K, 2026-06-02
Picard Medical, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-02 to 2026-11-03. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Picard Medical, Inc. files it.
Also on the record for Picard Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G/A, by Hudson Bay Capital Management LP | 9.99% of the class | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G/A, by Sindex SSI Lending, LLC | — | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Hudson Bay Capital Management LP | 8.68% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Sindex SSI Lending, LLC | 10.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Picard Medical, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Picard Medical, Inc. and the records around it.
Picard Medical, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Hudson Bay Capital Management LP also filed stake reports on 34 other companies: Newbridge Acquisition Ltd (Nov 2026), Eos Energy Enterprises, Inc. (Nov 2026), FG Imperii Acquisition Corp. (Nov 2026)
Watch Picard Medical, Inc.
Get an email when Picard Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Picard Medical, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Picard Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Picard Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | In | Chief Executive Officer | 8-K, 2026-11-03 | ||
| 2026-07-07 | In | Director | 8-K/A, 2026-07-07 | ||
| 2026-06-29 | In | 8-K, 2026-06-29 | |||
| 2026-06-24 | In | Chief Executive Officer | 8-K, 2026-06-24 | ||
| 2026-06-02 | In | Chief Accounting Officer | 2026-06-01 | 8-K, 2026-06-02 |
Who leads Picard Medical, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Richard Fang, appointed (filed 2026-11-03).
- Director: Joe Xiao, appointed (filed 2026-07-07).
- Chief Accounting Officer: Georgina Smith, appointed, effective 2026-06-01 (filed 2026-06-02).
New leaders reset buying decisions — get the Full Report on Picard Medical, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Picard Medical, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Picard Medical, Inc.Every change, in the filing's words
Appointed: Richard Fang, Chief Executive Officer
On October 28, 2026, the Board of Directors (the "Board") of Picard Medical, Inc., a Delaware company (the "Company") appointed Richard Fang, Ph.D., as the Company's Chief Executive Officer on a permanent, full-time basis, effective as of the same date.
- Dr. Fang has served as Interim Chief Executive Officer since June 18, 2026 and will continue to serve as Chairman of the Board.
- Dr. Fang, age 60, has served on the Board since September 2021 and previously served as the Company's Chief Executive Officer from September 2021 to July 2023.
- He is a founder and managing partner of Hunniwell Lake Ventures LLC, a medical technology-focused venture capital firm founded in 2019.
- In 2005, Dr. Fang founded Reach Surgical, a California-based minimally invasive surgical instruments company.
- Over 15 years, he led its growth and expansion across six continents and managed the full lifecycle of three product lines.
- His tenure culminated in the company's sale to a private equity buyer.
- He has more than 20 years of medical device industry experience, including at Johnson & Johnson.
- He holds an MBA from the University of Cincinnati and a Ph.D. in Physics from Purdue University in Indianapolis.
- The appointment involved no new or amended compensation or employment arrangement and no additional compensation or award.
- Related-Person Loans In February 2026, the Company borrowed $0.7 million from Fang Family Fund I, LLC, an entity affiliated with Dr. Fang, under a loan agreement ("Note") which bears 6% interest per annum.
Appointed: Joe Xiao, Director
On June 23, 2026, the Board appointed Dr. Joe Xiao to serve as a member of the Board, effective as of such date.
- In connection with his appointment to the Board, Dr. Xiao was also appointed to serve as a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.
- In connection with being appointed to the Board, Dr. Xiao entered into the Company's standard indemnification agreement for directors.
- Dr. Xiao will receive compensation in accordance with the Company's existing compensation policy for non-employee directors, which is described under "The Board, Its Committees and Its Compensation - Director Compensation" in the Company's proxy statement filed with the the SEC on June 15, 2026.
Appointed: Joe Xiao
On June 23, 2026, Dr. Joe Xiao was appointed to the Board of Directors (the "Board") of Picard Medical, Inc. (the "Company") with a term set to expire at the 2026 annual meeting of stockholders.
- Dr. Xiao has also been appointed to the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee.
- In connection with being appointed to the Board, Dr. Xiao entered into the Company's standard indemnification agreement for directors.
- Dr. Xiao will receive compensation in accordance with the Company's existing compensation policy for non-employee directors, which is described under "The Board, Its Committees and Its Compensation - Director Compensation" in the Company's proxy statement filed with the Securities and Exchange Commission (the "SEC") on June 15, 2026.
Appointed: Richard Fang, Chief Executive Officer
The Board appointed Richard Fang, Ph.D., 60, as the Company's Interim Chief Executive Officer, effective as of the Separation Date.
- On June 17, 2026, Patrick NJ Schnegelsberg notified Picard Medical, Inc. (the "Company") of his decision to step down as Chief Executive Officer and as a member of the Board of Directors of the Company (the "Board"), effective June 18, 2026 (the "Separation Date"), in connection with a planned leadership transition.
- Mr. Schnegelsberg's departure was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.
- The Board thanks Mr. Schnegelsberg for his service and his contributions during a formative period for the Company.
- Dr. Fang, former Chief Executive Officer and current Chairman of the Board, will serve as Interim Chief Executive Officer until a permanent successor has been appointed by the Board, and will continue to serve in his current role as Chairman.
- Dr. Fang served as the Chief Executive Officer from September 2021 until July 2023.
- Dr. Fang has served as a member of the Board since September 2021.
- Dr. Fang is a founder and managing partner of Hunniwell Lake Ventures LLC, a med-tech focused venture capital firm founded in 2019.
- In 2005, Dr. Fang founded Reach Surgical, a minimally invasive surgical instruments company in California.
- He directed the growth and international expansion of Reach Surgical over a 15-year period, building a globally recognized brand presence across six continents.
Appointed: Georgina Smith, Chief Accounting Officer, effective 2026-06-01
The Board of Directors of the Company appointed Georgina Smith, 54, as the Company's Chief Accounting Officer, effective June 1, 2026.
- Also as of June 1, 2026, Bernard Skaggs was terminated as the Chief Financial Officer of Picard Medical, Inc. (the "Company"), effective immediately.
- Prior to her appointment, Ms. Smith served as Controller of SynCardia Systems, LLC, a subsidiary of the Company, ("SynCardia") from January 2026 to May 2026.
- Before joining SynCardia, Ms. Smith served as Assistant Corporate Controller of Rain Bird Corporation from January 2024 to October 2025, where she was responsible for enterprise accounting governance, internal controls, financial reporting, regulatory compliance, and audit readiness.
- From May 2014 to December 2023, she held positions of increasing responsibility at Tucson Electric Power, including Manager of External Reporting from January 2018 to December 2023.
- Ms. Smith holds a Master of Business Administration and a Bachelor of Science in Accounting from the University of Arizona and is a Certified Public Accountant in the State of Arizona.
Tools for this story
Each opens in a new tab, filled in for Picard Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.